Objective:To study the effect of kushenin combined with entecavir therapy on hepatic fibrosis and immune response in patients with chronic hepatitis B.Methods: Patients who were diagnosed with chronic viral hepatitis ...Objective:To study the effect of kushenin combined with entecavir therapy on hepatic fibrosis and immune response in patients with chronic hepatitis B.Methods: Patients who were diagnosed with chronic viral hepatitis B in First Affiliated Hospital of PLA General Hospital between March 2015 and June 2017 were enrolled in the study and randomly divided into the experimental group who kushenin combined with entecavir therapy and the control group who received entecavir monotherapy. The levels of hepatic fibrosis indexes and immune cytokines in serum as well as the number of immune cells in peripheral blood were measured before treatment as well as 3 months and 6 months after treatment.Results: Compared with the corresponding indexes of same group before treatment, serum PC-III, C-IV, TGF-β1, Ang-II and IFN-γ levels as well as peripheral blood Th1 cell number of both groups of patients were significantly lower whereas Th2, mDC and pDC cell number as well as CD80 and CD86 expression intensity in peripheral blood as well as IL-5 and IL-10 levels in serum were significantly higher 3 months and 6 months after treatment;serum PC-III, C-IV, TGF-β1, Ang-II and IFN-γ levels as well as peripheral blood Th1 cell number of experimental group 3 months and 6 months after treatment were significantly lower than those of control group whereas Th2, mDC and pDC cell number as well as CD80 and CD86 expression intensity in peripheral blood as well as IL-5 and IL-10 levels in serum were significantly higher than those of control group.Conclusions: kushenin combined with entecavir treatment of chronic hepatitis B can delay hepatic fibrosis progression and improve immune response.展开更多
Objective： To evaluate the efficacy of kushenin in treating patients with chronic hepatitis C after renal transplantation. Methods： Fifty-five patients were randomly assigned by lottery to the treatment group （29 c...Objective： To evaluate the efficacy of kushenin in treating patients with chronic hepatitis C after renal transplantation. Methods： Fifty-five patients were randomly assigned by lottery to the treatment group （29 cases） and control group （26 cases）. The same immunosuppression therapy was given to all patients in both groups. Patients in the treatment group were treated with kushenin 0.6 g once a day, while those in the control group were treated with conventional liver protective agents such as vitamins. The treatment duration of both groups was 3 months. The incidences of serious hepatitis and acute rejection reaction, serum biochemistry parameters including indicators of liver and kidney functions, hepatic fibrosis index, and serum HCV-RNA were compared between the two groups. Results： （1） The incidence of serious hepatitis in the treatment group and the control group was 3.45% （1/29 cases） and 11.54% （3/26 cases）, respectively, which was insignificantly different between the two groups （P=0.335）. （2） The incidence of acute rejection in the treatment group was 6.90% （2/29 cases） and that in the control group was 7.69% （2/26 cases）, showing insignificant difference （P=0.335）. （3） The differences in serum alanine aminotransferase （ALT）, direct bilirubin （DBIL）, hyaluronic acid （HA）, propeptide collagen type Ⅲ （PC Ⅲ）, laminin （LN）, collagen type Ⅳ（Col Ⅳ） levels between the two groups were insignificant before transplantation （P〉0.05）, while the above-mentioned parameters in the treatment group were significantly lower than those in the control group after transplantation （P〈0.05）. The difference in serum creatinine （SCr） and endogenous creatinine clearance rate （CCr） between the two groups was insignificant before and after transplantation （P〉0.05）. （4） The negative conversion rate of HCV-RNA in the treatment group was 31.03% （9/29 cases）, significantly higher than the value of 11.54% （3/26 cases） in the control group after transplantation （P〈0.05）. （5） The levels of serum ALT and DBIL in patients with HCV-RNA converted to negative were significantly lower than those with still-positive HCV-RNA （P〈0.05）. Conclusions： Kushenin has a certain effect on inhibiting the proliferation of HCV, protecting liver cells, and anti-liver fibrosis. On the other hand, it has no obvious influence on renal allograft function. Thus, the drug is clinically safe and effective for use in treating patients with chronic hepatitis C after renal transplantation.展开更多
目的:探讨恩替卡韦联合苦参素对HBe Ag阳性慢性乙型肝炎(chronic hepatitis B,CHB)患者Th1/Th2失平衡的影响。方法:将216例HBe Ag阳性CHB患者随机分为治疗组和对照组。治疗组112例给予恩替卡韦联合苦参素治疗,对照组104例给予恩替卡韦治...目的:探讨恩替卡韦联合苦参素对HBe Ag阳性慢性乙型肝炎(chronic hepatitis B,CHB)患者Th1/Th2失平衡的影响。方法:将216例HBe Ag阳性CHB患者随机分为治疗组和对照组。治疗组112例给予恩替卡韦联合苦参素治疗,对照组104例给予恩替卡韦治疗,疗程48周。治疗48周后,应用ELISA检测患者外周血Th1型细胞因子(IFN-γ、IL-2)和Th2型细胞因子(IL-4、IL-10)的表达水平,应用实时定量PCR检测患者外周血Th1细胞特征性转录因子(T-bet)和Th2细胞特征性转录因子(GATA3)mRNA的表达水平。结果:治疗48周后,治疗组IFN-γ、IL-2的表达水平较对照组明显升高[(68.32±9.67)pg/m L vs(35.24±7.49)pg/m L,(216.81±31.55)pg/m L vs(115.63±29.13)pg/m L;t1=27.96,t2=24.43;P1、P2均<0.01];而治疗组IL-4、IL-10的表达水平较对照组明显降低[(18.79±5.83)pg/m L vs(22.58±5.32)pg/m L,(133.75±29.21)pg/m L vs(143.17±32.96)pg/m L;t3=4.98,t4=2.23;P3<0.01,P4<0.05]。治疗组IFN-γ与IL-4比值IFN-γ/IL-4较对照组明显增大(3.59±0.76 vs 1.61±0.53,t=22.05,P<0.01)。治疗48周后,治疗组T-bet mRNA的表达水平较对照组明显升高(1.52±0.41 vs 0.83±0.29,t=14.18,P<0.01);而治疗组GATA3 mRNA的表达水平较对照组明显降低(0.96±0.24 vs 1.05±0.37,t=2.14,P<0.05)。治疗组T-bet mRNA与GATA3 mRNA比值T-bet/GATA3较对照组明显增大(1.60±0.39 vs 0.81±0.32,t=16.20,P<0.01)。结论:恩替卡韦联合苦参素可以促进HBe Ag阳性CHB患者Th1型细胞因子的分泌,抑制Th2型细胞因子的分泌,促使HBe Ag阳性CHB患者外周血Th细胞向Th1细胞分化,使其Th1/Th2失平衡得到改善。展开更多
目的探讨苦参素对裸鼠增生性瘢痕的抑制作用及其有效作用机制,为该药的临床应用提供理论依据。方法用人源增生性瘢痕移植方法 ,制备增生性瘢痕裸鼠模型,术后10 d,裸鼠30只,随机分为模型组、苦参素涂膜剂组、阳性药组,药物组分别涂抹苦...目的探讨苦参素对裸鼠增生性瘢痕的抑制作用及其有效作用机制,为该药的临床应用提供理论依据。方法用人源增生性瘢痕移植方法 ,制备增生性瘢痕裸鼠模型,术后10 d,裸鼠30只,随机分为模型组、苦参素涂膜剂组、阳性药组,药物组分别涂抹苦参素涂膜剂和阳性药,每天2次,连续8周;对照组涂抹基质。每周观察并拍照记录瘢痕的生长情况,于术后10、35、49、56 d测量瘢痕面积,RT-PCR检测组织中的TGF-β1、Smad3的表达,Western-blot方法检测TGF-β1和Smad3蛋白的表达。结果模型对照组瘢痕生长较快,愈合较慢,阳性药和苦参素涂膜剂组,瘢痕生长显著被抑制,随着用药时间的延长,其抑制作用明显增强。与模型对照组相比,苦参素涂膜剂组的TGF-β1、Smad3 m RNA和蛋白的表达量明显下降。结论苦参素涂膜剂能抑制增生性瘢痕的生长并下调TGF-β1、Smad3 m RNA和蛋白的表达,调控TGF-β/Smad信号通路表达可能是苦参素抑制增生性瘢痕的机制之一。展开更多
基金Youth Science Fund Projects of the Natural Science Foundation of China(No:81600476).
文摘Objective:To study the effect of kushenin combined with entecavir therapy on hepatic fibrosis and immune response in patients with chronic hepatitis B.Methods: Patients who were diagnosed with chronic viral hepatitis B in First Affiliated Hospital of PLA General Hospital between March 2015 and June 2017 were enrolled in the study and randomly divided into the experimental group who kushenin combined with entecavir therapy and the control group who received entecavir monotherapy. The levels of hepatic fibrosis indexes and immune cytokines in serum as well as the number of immune cells in peripheral blood were measured before treatment as well as 3 months and 6 months after treatment.Results: Compared with the corresponding indexes of same group before treatment, serum PC-III, C-IV, TGF-β1, Ang-II and IFN-γ levels as well as peripheral blood Th1 cell number of both groups of patients were significantly lower whereas Th2, mDC and pDC cell number as well as CD80 and CD86 expression intensity in peripheral blood as well as IL-5 and IL-10 levels in serum were significantly higher 3 months and 6 months after treatment;serum PC-III, C-IV, TGF-β1, Ang-II and IFN-γ levels as well as peripheral blood Th1 cell number of experimental group 3 months and 6 months after treatment were significantly lower than those of control group whereas Th2, mDC and pDC cell number as well as CD80 and CD86 expression intensity in peripheral blood as well as IL-5 and IL-10 levels in serum were significantly higher than those of control group.Conclusions: kushenin combined with entecavir treatment of chronic hepatitis B can delay hepatic fibrosis progression and improve immune response.
基金National Natural Science Foundation of China(No.30571799,30471640)
文摘Objective： To evaluate the efficacy of kushenin in treating patients with chronic hepatitis C after renal transplantation. Methods： Fifty-five patients were randomly assigned by lottery to the treatment group （29 cases） and control group （26 cases）. The same immunosuppression therapy was given to all patients in both groups. Patients in the treatment group were treated with kushenin 0.6 g once a day, while those in the control group were treated with conventional liver protective agents such as vitamins. The treatment duration of both groups was 3 months. The incidences of serious hepatitis and acute rejection reaction, serum biochemistry parameters including indicators of liver and kidney functions, hepatic fibrosis index, and serum HCV-RNA were compared between the two groups. Results： （1） The incidence of serious hepatitis in the treatment group and the control group was 3.45% （1/29 cases） and 11.54% （3/26 cases）, respectively, which was insignificantly different between the two groups （P=0.335）. （2） The incidence of acute rejection in the treatment group was 6.90% （2/29 cases） and that in the control group was 7.69% （2/26 cases）, showing insignificant difference （P=0.335）. （3） The differences in serum alanine aminotransferase （ALT）, direct bilirubin （DBIL）, hyaluronic acid （HA）, propeptide collagen type Ⅲ （PC Ⅲ）, laminin （LN）, collagen type Ⅳ（Col Ⅳ） levels between the two groups were insignificant before transplantation （P〉0.05）, while the above-mentioned parameters in the treatment group were significantly lower than those in the control group after transplantation （P〈0.05）. The difference in serum creatinine （SCr） and endogenous creatinine clearance rate （CCr） between the two groups was insignificant before and after transplantation （P〉0.05）. （4） The negative conversion rate of HCV-RNA in the treatment group was 31.03% （9/29 cases）, significantly higher than the value of 11.54% （3/26 cases） in the control group after transplantation （P〈0.05）. （5） The levels of serum ALT and DBIL in patients with HCV-RNA converted to negative were significantly lower than those with still-positive HCV-RNA （P〈0.05）. Conclusions： Kushenin has a certain effect on inhibiting the proliferation of HCV, protecting liver cells, and anti-liver fibrosis. On the other hand, it has no obvious influence on renal allograft function. Thus, the drug is clinically safe and effective for use in treating patients with chronic hepatitis C after renal transplantation.
文摘目的:探讨恩替卡韦联合苦参素对HBe Ag阳性慢性乙型肝炎(chronic hepatitis B,CHB)患者Th1/Th2失平衡的影响。方法:将216例HBe Ag阳性CHB患者随机分为治疗组和对照组。治疗组112例给予恩替卡韦联合苦参素治疗,对照组104例给予恩替卡韦治疗,疗程48周。治疗48周后,应用ELISA检测患者外周血Th1型细胞因子(IFN-γ、IL-2)和Th2型细胞因子(IL-4、IL-10)的表达水平,应用实时定量PCR检测患者外周血Th1细胞特征性转录因子(T-bet)和Th2细胞特征性转录因子(GATA3)mRNA的表达水平。结果:治疗48周后,治疗组IFN-γ、IL-2的表达水平较对照组明显升高[(68.32±9.67)pg/m L vs(35.24±7.49)pg/m L,(216.81±31.55)pg/m L vs(115.63±29.13)pg/m L;t1=27.96,t2=24.43;P1、P2均<0.01];而治疗组IL-4、IL-10的表达水平较对照组明显降低[(18.79±5.83)pg/m L vs(22.58±5.32)pg/m L,(133.75±29.21)pg/m L vs(143.17±32.96)pg/m L;t3=4.98,t4=2.23;P3<0.01,P4<0.05]。治疗组IFN-γ与IL-4比值IFN-γ/IL-4较对照组明显增大(3.59±0.76 vs 1.61±0.53,t=22.05,P<0.01)。治疗48周后,治疗组T-bet mRNA的表达水平较对照组明显升高(1.52±0.41 vs 0.83±0.29,t=14.18,P<0.01);而治疗组GATA3 mRNA的表达水平较对照组明显降低(0.96±0.24 vs 1.05±0.37,t=2.14,P<0.05)。治疗组T-bet mRNA与GATA3 mRNA比值T-bet/GATA3较对照组明显增大(1.60±0.39 vs 0.81±0.32,t=16.20,P<0.01)。结论:恩替卡韦联合苦参素可以促进HBe Ag阳性CHB患者Th1型细胞因子的分泌,抑制Th2型细胞因子的分泌,促使HBe Ag阳性CHB患者外周血Th细胞向Th1细胞分化,使其Th1/Th2失平衡得到改善。
文摘目的探讨苦参素对裸鼠增生性瘢痕的抑制作用及其有效作用机制,为该药的临床应用提供理论依据。方法用人源增生性瘢痕移植方法 ,制备增生性瘢痕裸鼠模型,术后10 d,裸鼠30只,随机分为模型组、苦参素涂膜剂组、阳性药组,药物组分别涂抹苦参素涂膜剂和阳性药,每天2次,连续8周;对照组涂抹基质。每周观察并拍照记录瘢痕的生长情况,于术后10、35、49、56 d测量瘢痕面积,RT-PCR检测组织中的TGF-β1、Smad3的表达,Western-blot方法检测TGF-β1和Smad3蛋白的表达。结果模型对照组瘢痕生长较快,愈合较慢,阳性药和苦参素涂膜剂组,瘢痕生长显著被抑制,随着用药时间的延长,其抑制作用明显增强。与模型对照组相比,苦参素涂膜剂组的TGF-β1、Smad3 m RNA和蛋白的表达量明显下降。结论苦参素涂膜剂能抑制增生性瘢痕的生长并下调TGF-β1、Smad3 m RNA和蛋白的表达,调控TGF-β/Smad信号通路表达可能是苦参素抑制增生性瘢痕的机制之一。
